| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Opioid-Related Disorders | 95 | 2024 | 2064 | 11.340 |
Why?
|
| Substance-Related Disorders | 151 | 2024 | 4257 | 10.830 |
Why?
|
| Buprenorphine | 37 | 2024 | 640 | 7.510 |
Why?
|
| Alcoholism | 53 | 2020 | 1906 | 4.830 |
Why?
|
| Opiate Substitution Treatment | 22 | 2023 | 404 | 4.290 |
Why?
|
| Narcotic Antagonists | 27 | 2024 | 562 | 4.030 |
Why?
|
| Analgesics, Opioid | 53 | 2024 | 3677 | 3.870 |
Why?
|
| Cocaine-Related Disorders | 33 | 2020 | 460 | 3.680 |
Why?
|
| Naloxone | 17 | 2022 | 367 | 3.660 |
Why?
|
| Bipolar Disorder | 48 | 2019 | 5027 | 3.450 |
Why?
|
| Cocaine | 31 | 2023 | 1007 | 2.860 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 39 | 2016 | 295 | 2.220 |
Why?
|
| Psychotherapy | 21 | 2020 | 1642 | 2.210 |
Why?
|
| Psychotherapy, Group | 20 | 2021 | 406 | 2.120 |
Why?
|
| Heroin Dependence | 9 | 2017 | 175 | 1.600 |
Why?
|
| Substance Withdrawal Syndrome | 15 | 2018 | 632 | 1.560 |
Why?
|
| Self-Help Groups | 10 | 2019 | 190 | 1.550 |
Why?
|
| Alcohol-Related Disorders | 8 | 2016 | 234 | 1.510 |
Why?
|
| Prescription Drugs | 10 | 2014 | 595 | 1.480 |
Why?
|
| Counseling | 18 | 2021 | 1523 | 1.430 |
Why?
|
| Benzodiazepines | 8 | 2022 | 1101 | 1.370 |
Why?
|
| Marijuana Abuse | 11 | 2020 | 403 | 1.350 |
Why?
|
| Behavior Therapy | 9 | 2017 | 865 | 1.260 |
Why?
|
| Substance Abuse Detection | 11 | 2014 | 283 | 1.220 |
Why?
|
| Substance Abuse Treatment Centers | 10 | 2014 | 168 | 1.210 |
Why?
|
| Endocarditis | 3 | 2020 | 349 | 1.200 |
Why?
|
| Adult | 204 | 2024 | 214052 | 1.200 |
Why?
|
| Cognition Disorders | 9 | 2012 | 4043 | 1.190 |
Why?
|
| Anxiety Disorders | 16 | 2021 | 2690 | 1.160 |
Why?
|
| Alcohol Deterrents | 7 | 2016 | 39 | 1.140 |
Why?
|
| Humans | 318 | 2024 | 744366 | 1.010 |
Why?
|
| Clinical Trials as Topic | 14 | 2023 | 7914 | 1.000 |
Why?
|
| Stress Disorders, Post-Traumatic | 18 | 2021 | 4266 | 0.990 |
Why?
|
| Sex Offenses | 3 | 2020 | 354 | 0.960 |
Why?
|
| Naltrexone | 11 | 2024 | 307 | 0.950 |
Why?
|
| Male | 214 | 2024 | 350115 | 0.950 |
Why?
|
| Catastrophization | 4 | 2020 | 316 | 0.930 |
Why?
|
| Female | 216 | 2024 | 380193 | 0.910 |
Why?
|
| Patient Compliance | 10 | 2020 | 2684 | 0.900 |
Why?
|
| Affect | 7 | 2013 | 1475 | 0.890 |
Why?
|
| Cannabis | 3 | 2021 | 440 | 0.890 |
Why?
|
| Psychiatric Status Rating Scales | 35 | 2016 | 6036 | 0.850 |
Why?
|
| Pharmaceutical Preparations | 2 | 2021 | 1070 | 0.850 |
Why?
|
| Anxiety | 12 | 2023 | 4293 | 0.840 |
Why?
|
| Comorbidity | 42 | 2019 | 10388 | 0.800 |
Why?
|
| Research Design | 14 | 2023 | 5984 | 0.790 |
Why?
|
| Depressive Disorder | 15 | 2019 | 3747 | 0.780 |
Why?
|
| Narcotics | 5 | 2013 | 343 | 0.770 |
Why?
|
| Treatment Refusal | 2 | 2020 | 421 | 0.760 |
Why?
|
| Receptors, Opioid, mu | 2 | 2021 | 182 | 0.750 |
Why?
|
| Unsafe Sex | 3 | 2013 | 220 | 0.740 |
Why?
|
| Pain | 14 | 2023 | 4988 | 0.740 |
Why?
|
| Cues | 3 | 2016 | 875 | 0.740 |
Why?
|
| Heroin | 6 | 2024 | 117 | 0.730 |
Why?
|
| Motivation | 11 | 2022 | 1971 | 0.720 |
Why?
|
| Behavior, Addictive | 5 | 2015 | 462 | 0.710 |
Why?
|
| Patient Acceptance of Health Care | 8 | 2015 | 3020 | 0.690 |
Why?
|
| Personal Satisfaction | 2 | 2023 | 643 | 0.690 |
Why?
|
| Societies, Scientific | 1 | 2020 | 220 | 0.690 |
Why?
|
| Substance Abuse, Intravenous | 3 | 2020 | 525 | 0.670 |
Why?
|
| Community Mental Health Services | 3 | 2011 | 386 | 0.670 |
Why?
|
| Models, Statistical | 4 | 2023 | 5101 | 0.650 |
Why?
|
| Cannabinoids | 1 | 2021 | 166 | 0.650 |
Why?
|
| Psychotropic Drugs | 7 | 2012 | 894 | 0.640 |
Why?
|
| Psychometrics | 17 | 2023 | 3003 | 0.620 |
Why?
|
| Young Adult | 48 | 2020 | 56429 | 0.620 |
Why?
|
| Psychiatry | 3 | 2020 | 1695 | 0.610 |
Why?
|
| Tobacco Use Disorder | 7 | 2024 | 688 | 0.610 |
Why?
|
| Combined Modality Therapy | 25 | 2017 | 8642 | 0.590 |
Why?
|
| Mood Disorders | 10 | 2019 | 1106 | 0.590 |
Why?
|
| Psychotic Disorders | 8 | 2022 | 3046 | 0.590 |
Why?
|
| Treatment Outcome | 53 | 2020 | 63107 | 0.580 |
Why?
|
| Legislation, Medical | 1 | 2017 | 100 | 0.580 |
Why?
|
| Middle Aged | 97 | 2022 | 213390 | 0.570 |
Why?
|
| Oxycodone | 3 | 2022 | 153 | 0.570 |
Why?
|
| Anniversaries and Special Events | 1 | 2017 | 89 | 0.570 |
Why?
|
| Linear Models | 3 | 2023 | 5953 | 0.560 |
Why?
|
| Taurine | 6 | 2016 | 94 | 0.560 |
Why?
|
| Neuropsychological Tests | 10 | 2013 | 6994 | 0.550 |
Why?
|
| Ambulatory Care | 12 | 2023 | 2708 | 0.540 |
Why?
|
| Drug Prescriptions | 5 | 2022 | 1637 | 0.540 |
Why?
|
| Irritable Mood | 1 | 2016 | 183 | 0.530 |
Why?
|
| Self Report | 10 | 2020 | 3553 | 0.530 |
Why?
|
| Mental Disorders | 17 | 2019 | 6598 | 0.520 |
Why?
|
| Pain Measurement | 7 | 2019 | 3420 | 0.520 |
Why?
|
| Community Mental Health Centers | 2 | 2013 | 102 | 0.520 |
Why?
|
| Self Medication | 5 | 2013 | 117 | 0.510 |
Why?
|
| Child Abuse | 6 | 2020 | 1030 | 0.510 |
Why?
|
| Social Support | 5 | 2011 | 2118 | 0.500 |
Why?
|
| Longitudinal Studies | 17 | 2023 | 13991 | 0.500 |
Why?
|
| Smoking Cessation | 5 | 2016 | 2071 | 0.500 |
Why?
|
| Urinalysis | 2 | 2014 | 369 | 0.490 |
Why?
|
| Severity of Illness Index | 23 | 2019 | 15535 | 0.490 |
Why?
|
| Endpoint Determination | 1 | 2017 | 601 | 0.490 |
Why?
|
| Inpatients | 3 | 2023 | 2518 | 0.490 |
Why?
|
| Methadone | 7 | 2023 | 306 | 0.470 |
Why?
|
| Secondary Prevention | 7 | 2023 | 1530 | 0.470 |
Why?
|
| Hospitalization | 20 | 2020 | 10259 | 0.460 |
Why?
|
| Adolescent | 54 | 2024 | 85779 | 0.460 |
Why?
|
| Residential Treatment | 2 | 2011 | 111 | 0.460 |
Why?
|
| Patient Dropouts | 5 | 2020 | 420 | 0.460 |
Why?
|
| Domestic Violence | 4 | 2009 | 176 | 0.460 |
Why?
|
| Restless Legs Syndrome | 1 | 2016 | 228 | 0.460 |
Why?
|
| Patient Discharge | 4 | 2020 | 3318 | 0.460 |
Why?
|
| Token Economy | 1 | 2013 | 17 | 0.450 |
Why?
|
| Follow-Up Studies | 28 | 2020 | 39052 | 0.450 |
Why?
|
| Depression | 7 | 2019 | 7759 | 0.440 |
Why?
|
| Social Adjustment | 2 | 2013 | 631 | 0.440 |
Why?
|
| Alcoholics Anonymous | 5 | 2008 | 35 | 0.420 |
Why?
|
| Disabled Persons | 1 | 2022 | 1212 | 0.410 |
Why?
|
| Adaptation, Psychological | 6 | 2022 | 2575 | 0.410 |
Why?
|
| Job Application | 1 | 2011 | 39 | 0.400 |
Why?
|
| Prevalence | 15 | 2020 | 15221 | 0.400 |
Why?
|
| Nicotine | 4 | 2023 | 681 | 0.400 |
Why?
|
| Suicide | 1 | 2022 | 1474 | 0.390 |
Why?
|
| Chi-Square Distribution | 8 | 2023 | 3508 | 0.390 |
Why?
|
| Personality Inventory | 6 | 2007 | 1030 | 0.380 |
Why?
|
| Patient Care Management | 1 | 2014 | 306 | 0.380 |
Why?
|
| United States | 40 | 2022 | 69872 | 0.360 |
Why?
|
| Outpatients | 6 | 2021 | 1487 | 0.360 |
Why?
|
| Risk-Taking | 3 | 2011 | 986 | 0.360 |
Why?
|
| Pilot Projects | 12 | 2023 | 8319 | 0.360 |
Why?
|
| Sleep Disorders, Circadian Rhythm | 1 | 2012 | 222 | 0.350 |
Why?
|
| Public Policy | 1 | 2014 | 572 | 0.350 |
Why?
|
| Attitude to Health | 4 | 2016 | 2052 | 0.350 |
Why?
|
| Euphoria | 2 | 2008 | 67 | 0.340 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 11 | 2024 | 1953 | 0.340 |
Why?
|
| Suicide, Attempted | 8 | 2019 | 1218 | 0.340 |
Why?
|
| Randomized Controlled Trials as Topic | 12 | 2020 | 9955 | 0.340 |
Why?
|
| Acupuncture Points | 1 | 2009 | 101 | 0.330 |
Why?
|
| Temperance | 6 | 2015 | 89 | 0.330 |
Why?
|
| Patient Preference | 2 | 2016 | 889 | 0.330 |
Why?
|
| Recurrence | 16 | 2016 | 8340 | 0.320 |
Why?
|
| Cognition | 4 | 2023 | 6770 | 0.320 |
Why?
|
| Education | 1 | 2011 | 543 | 0.310 |
Why?
|
| Affective Disorders, Psychotic | 1 | 2009 | 191 | 0.310 |
Why?
|
| Alcohol Drinking | 5 | 2016 | 3966 | 0.310 |
Why?
|
| Reproducibility of Results | 17 | 2023 | 19905 | 0.300 |
Why?
|
| Disulfiram | 2 | 2020 | 57 | 0.300 |
Why?
|
| National Institute on Drug Abuse (U.S.) | 6 | 2014 | 11 | 0.300 |
Why?
|
| Genetic Linkage | 6 | 2010 | 2421 | 0.300 |
Why?
|
| Cross-Sectional Studies | 20 | 2023 | 25039 | 0.300 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 3 | 2018 | 1004 | 0.300 |
Why?
|
| Transcutaneous Electric Nerve Stimulation | 1 | 2009 | 162 | 0.300 |
Why?
|
| Paranoid Disorders | 5 | 2011 | 60 | 0.290 |
Why?
|
| Central Nervous System Stimulants | 2 | 2013 | 1148 | 0.290 |
Why?
|
| N-Methyl-3,4-methylenedioxyamphetamine | 2 | 2009 | 65 | 0.280 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2007 | 281 | 0.280 |
Why?
|
| Hypnotics and Sedatives | 4 | 2018 | 1162 | 0.280 |
Why?
|
| Risk | 4 | 2016 | 9688 | 0.280 |
Why?
|
| Antipsychotic Agents | 5 | 2011 | 3057 | 0.280 |
Why?
|
| Deception | 1 | 2007 | 99 | 0.270 |
Why?
|
| Ecosystem | 1 | 2010 | 474 | 0.270 |
Why?
|
| Sex Characteristics | 3 | 2020 | 2585 | 0.270 |
Why?
|
| Adolescent Behavior | 3 | 2014 | 1151 | 0.270 |
Why?
|
| Periodicals as Topic | 1 | 2017 | 1431 | 0.270 |
Why?
|
| Self Efficacy | 2 | 2019 | 615 | 0.270 |
Why?
|
| Interview, Psychological | 6 | 2011 | 812 | 0.270 |
Why?
|
| Executive Function | 5 | 2013 | 1364 | 0.260 |
Why?
|
| Anti-Anxiety Agents | 3 | 2018 | 390 | 0.260 |
Why?
|
| Drug Therapy | 2 | 2005 | 497 | 0.260 |
Why?
|
| Sex Factors | 14 | 2019 | 10400 | 0.250 |
Why?
|
| Sexual Behavior | 2 | 2011 | 2055 | 0.250 |
Why?
|
| Massachusetts | 13 | 2020 | 8662 | 0.250 |
Why?
|
| Medication Adherence | 3 | 2011 | 2063 | 0.250 |
Why?
|
| Employment | 2 | 2011 | 1132 | 0.250 |
Why?
|
| Likelihood Functions | 2 | 2023 | 1005 | 0.240 |
Why?
|
| Multicenter Studies as Topic | 3 | 2018 | 1677 | 0.240 |
Why?
|
| Information Services | 1 | 2005 | 244 | 0.240 |
Why?
|
| Attention | 6 | 2013 | 2397 | 0.230 |
Why?
|
| Lithium | 2 | 1998 | 601 | 0.230 |
Why?
|
| Hallucinogens | 2 | 2009 | 180 | 0.230 |
Why?
|
| Patient Selection | 5 | 2011 | 4216 | 0.230 |
Why?
|
| Borderline Personality Disorder | 1 | 2010 | 736 | 0.230 |
Why?
|
| Primary Health Care | 7 | 2022 | 4557 | 0.230 |
Why?
|
| Drug Therapy, Combination | 6 | 2016 | 6489 | 0.230 |
Why?
|
| Antidepressive Agents | 2 | 2012 | 2838 | 0.220 |
Why?
|
| Mass Screening | 6 | 2023 | 5253 | 0.220 |
Why?
|
| Hydrocodone | 1 | 2022 | 47 | 0.210 |
Why?
|
| Quality of Life | 8 | 2023 | 12802 | 0.210 |
Why?
|
| Memory | 5 | 2013 | 2174 | 0.210 |
Why?
|
| District of Columbia | 1 | 2022 | 157 | 0.210 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2016 | 3922 | 0.210 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 6 | 2010 | 3658 | 0.200 |
Why?
|
| Achievement | 1 | 2003 | 291 | 0.200 |
Why?
|
| Stress, Psychological | 2 | 2017 | 4245 | 0.200 |
Why?
|
| Feasibility Studies | 6 | 2022 | 5077 | 0.200 |
Why?
|
| Quality Assurance, Health Care | 2 | 2011 | 2212 | 0.200 |
Why?
|
| Pregnancy Complications | 2 | 2015 | 2861 | 0.200 |
Why?
|
| Life Change Events | 4 | 2009 | 938 | 0.200 |
Why?
|
| Hospitals, Psychiatric | 6 | 2017 | 332 | 0.190 |
Why?
|
| Risk Factors | 23 | 2022 | 72296 | 0.190 |
Why?
|
| Mental Health Services | 5 | 2019 | 1644 | 0.190 |
Why?
|
| Remission, Spontaneous | 2 | 2012 | 382 | 0.190 |
Why?
|
| Receptors, Serotonin | 1 | 2001 | 201 | 0.190 |
Why?
|
| Self-Injurious Behavior | 1 | 2006 | 464 | 0.190 |
Why?
|
| Pyridines | 1 | 2012 | 2825 | 0.190 |
Why?
|
| Patient Admission | 5 | 2008 | 1380 | 0.180 |
Why?
|
| Health Status | 6 | 2015 | 4034 | 0.180 |
Why?
|
| Drug Users | 2 | 2020 | 134 | 0.180 |
Why?
|
| Computer Simulation | 3 | 2023 | 6194 | 0.180 |
Why?
|
| Time Factors | 11 | 2019 | 40075 | 0.180 |
Why?
|
| Socioeconomic Factors | 8 | 2015 | 7785 | 0.180 |
Why?
|
| Multivariate Analysis | 6 | 2013 | 12244 | 0.180 |
Why?
|
| Drive | 1 | 2019 | 35 | 0.180 |
Why?
|
| Referral and Consultation | 4 | 2015 | 3531 | 0.180 |
Why?
|
| Normal Distribution | 1 | 2020 | 280 | 0.180 |
Why?
|
| Personality Disorders | 2 | 1995 | 713 | 0.180 |
Why?
|
| Seizures | 1 | 2012 | 2859 | 0.180 |
Why?
|
| Comprehension | 1 | 2005 | 610 | 0.180 |
Why?
|
| Crime | 3 | 2018 | 215 | 0.180 |
Why?
|
| Aged | 23 | 2022 | 163288 | 0.170 |
Why?
|
| Prognosis | 13 | 2019 | 29060 | 0.170 |
Why?
|
| Quality of Health Care | 2 | 2005 | 4369 | 0.170 |
Why?
|
| Attitude of Health Personnel | 1 | 2013 | 3841 | 0.170 |
Why?
|
| Patient Education as Topic | 3 | 2006 | 2278 | 0.170 |
Why?
|
| Pain Threshold | 2 | 2016 | 584 | 0.160 |
Why?
|
| Chromosomes, Human, Pair 10 | 2 | 2010 | 287 | 0.160 |
Why?
|
| Photic Stimulation | 2 | 2016 | 2026 | 0.160 |
Why?
|
| Ethanol | 4 | 2023 | 1342 | 0.160 |
Why?
|
| Odds Ratio | 4 | 2020 | 9849 | 0.150 |
Why?
|
| Analysis of Variance | 5 | 2013 | 6366 | 0.150 |
Why?
|
| Perception | 1 | 2004 | 1198 | 0.150 |
Why?
|
| Factor Analysis, Statistical | 4 | 2021 | 977 | 0.150 |
Why?
|
| Data Interpretation, Statistical | 4 | 2013 | 2716 | 0.150 |
Why?
|
| Spiritual Therapies | 1 | 2017 | 58 | 0.140 |
Why?
|
| Practice Guidelines as Topic | 3 | 2017 | 7282 | 0.140 |
Why?
|
| Nursing Care | 1 | 2017 | 74 | 0.140 |
Why?
|
| Risperidone | 1 | 1999 | 383 | 0.140 |
Why?
|
| Injections | 1 | 2020 | 840 | 0.140 |
Why?
|
| Emergency Service, Hospital | 2 | 2014 | 7658 | 0.140 |
Why?
|
| Adult Survivors of Child Abuse | 1 | 2020 | 260 | 0.140 |
Why?
|
| Medication Therapy Management | 1 | 2017 | 127 | 0.140 |
Why?
|
| Logistic Models | 6 | 2020 | 13409 | 0.140 |
Why?
|
| Case Management | 2 | 2019 | 286 | 0.140 |
Why?
|
| Electronic Prescribing | 1 | 2017 | 121 | 0.140 |
Why?
|
| Long-Term Care | 2 | 2017 | 607 | 0.140 |
Why?
|
| HIV Infections | 4 | 2013 | 16715 | 0.140 |
Why?
|
| Predictive Value of Tests | 7 | 2012 | 15078 | 0.130 |
Why?
|
| Patient Participation | 1 | 2005 | 1457 | 0.130 |
Why?
|
| Prospective Studies | 11 | 2017 | 53290 | 0.130 |
Why?
|
| Methylphenidate | 2 | 2010 | 473 | 0.130 |
Why?
|
| Valproic Acid | 1 | 1998 | 445 | 0.130 |
Why?
|
| Prejudice | 1 | 2019 | 570 | 0.130 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2019 | 711 | 0.120 |
Why?
|
| Pulmonary Diffusing Capacity | 2 | 1987 | 88 | 0.120 |
Why?
|
| Age Factors | 8 | 2019 | 18373 | 0.120 |
Why?
|
| Smoking | 5 | 2020 | 8987 | 0.120 |
Why?
|
| Telemedicine | 2 | 2022 | 2872 | 0.120 |
Why?
|
| Intelligence | 2 | 2011 | 920 | 0.120 |
Why?
|
| History, 21st Century | 1 | 2020 | 1534 | 0.120 |
Why?
|
| Universities | 1 | 2019 | 951 | 0.120 |
Why?
|
| Amphetamine-Related Disorders | 1 | 2014 | 67 | 0.120 |
Why?
|
| Religion | 1 | 2017 | 356 | 0.120 |
Why?
|
| Suicidal Ideation | 2 | 2022 | 1246 | 0.120 |
Why?
|
| Health Surveys | 3 | 2016 | 4036 | 0.120 |
Why?
|
| Fructose | 1 | 2016 | 289 | 0.120 |
Why?
|
| Withholding Treatment | 1 | 2018 | 599 | 0.120 |
Why?
|
| Retrospective Studies | 15 | 2023 | 77460 | 0.120 |
Why?
|
| Professional-Patient Relations | 2 | 2001 | 737 | 0.110 |
Why?
|
| Data Collection | 3 | 2013 | 3339 | 0.110 |
Why?
|
| Corpus Striatum | 1 | 2019 | 1221 | 0.110 |
Why?
|
| Psychological Tests | 4 | 2007 | 651 | 0.110 |
Why?
|
| Managed Care Programs | 2 | 2013 | 950 | 0.110 |
Why?
|
| Antimanic Agents | 2 | 2009 | 522 | 0.110 |
Why?
|
| Sickness Impact Profile | 1 | 2014 | 302 | 0.110 |
Why?
|
| Memory, Short-Term | 2 | 2011 | 977 | 0.110 |
Why?
|
| Acetylcysteine | 1 | 2014 | 271 | 0.110 |
Why?
|
| Patient Satisfaction | 2 | 2021 | 3395 | 0.110 |
Why?
|
| Self Concept | 2 | 2018 | 1025 | 0.110 |
Why?
|
| Anticonvulsants | 2 | 2018 | 1916 | 0.110 |
Why?
|
| Regression Analysis | 5 | 2013 | 6459 | 0.110 |
Why?
|
| Survivors | 2 | 2022 | 2291 | 0.110 |
Why?
|
| Dreams | 1 | 2014 | 147 | 0.110 |
Why?
|
| Diagnosis, Differential | 5 | 2012 | 12961 | 0.110 |
Why?
|
| Sexual Partners | 2 | 2009 | 729 | 0.110 |
Why?
|
| Schizophrenia | 3 | 2007 | 6882 | 0.110 |
Why?
|
| History, 20th Century | 1 | 2020 | 2740 | 0.110 |
Why?
|
| Therapeutic Community | 1 | 2011 | 20 | 0.100 |
Why?
|
| Catechol O-Methyltransferase | 2 | 2011 | 245 | 0.100 |
Why?
|
| Prolactin | 1 | 1994 | 669 | 0.100 |
Why?
|
| Community Health Services | 3 | 2011 | 650 | 0.100 |
Why?
|
| Desipramine | 2 | 1989 | 184 | 0.100 |
Why?
|
| Polymorphism, Single Nucleotide | 9 | 2011 | 15520 | 0.100 |
Why?
|
| Haplotypes | 5 | 2011 | 2779 | 0.100 |
Why?
|
| Chronic Disease | 5 | 2009 | 9145 | 0.100 |
Why?
|
| Statistics as Topic | 2 | 2008 | 2373 | 0.100 |
Why?
|
| Models, Psychological | 1 | 2015 | 811 | 0.090 |
Why?
|
| Depressive Disorder, Major | 4 | 2019 | 4639 | 0.090 |
Why?
|
| Gene Frequency | 8 | 2010 | 3587 | 0.090 |
Why?
|
| Confidence Intervals | 2 | 2009 | 2971 | 0.090 |
Why?
|
| Alcohol-Induced Disorders, Nervous System | 1 | 2010 | 11 | 0.090 |
Why?
|
| Manuals as Topic | 3 | 2000 | 98 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2013 | 10943 | 0.090 |
Why?
|
| Drug Administration Schedule | 2 | 2009 | 4933 | 0.090 |
Why?
|
| Cause of Death | 1 | 2020 | 3582 | 0.090 |
Why?
|
| Health Care Surveys | 2 | 2021 | 2453 | 0.090 |
Why?
|
| Reading | 1 | 2014 | 558 | 0.090 |
Why?
|
| Biomedical Research | 2 | 2020 | 3309 | 0.090 |
Why?
|
| Milieu Therapy | 1 | 1989 | 3 | 0.090 |
Why?
|
| Delayed-Action Preparations | 3 | 2013 | 968 | 0.090 |
Why?
|
| United States Food and Drug Administration | 1 | 2017 | 1584 | 0.090 |
Why?
|
| Mannosidases | 1 | 2009 | 22 | 0.090 |
Why?
|
| Gender Identity | 1 | 2015 | 687 | 0.090 |
Why?
|
| Vermont | 1 | 2009 | 85 | 0.090 |
Why?
|
| New Hampshire | 1 | 2009 | 172 | 0.080 |
Why?
|
| Negativism | 1 | 2008 | 24 | 0.080 |
Why?
|
| Personality Assessment | 4 | 2006 | 647 | 0.080 |
Why?
|
| Cyclothymic Disorder | 2 | 2004 | 41 | 0.080 |
Why?
|
| Guideline Adherence | 2 | 2017 | 2265 | 0.080 |
Why?
|
| Carbon Monoxide | 2 | 2013 | 531 | 0.080 |
Why?
|
| Health Literacy | 1 | 2014 | 414 | 0.080 |
Why?
|
| Psychology | 1 | 2010 | 356 | 0.080 |
Why?
|
| Directive Counseling | 1 | 2010 | 166 | 0.080 |
Why?
|
| Goals | 3 | 2009 | 707 | 0.080 |
Why?
|
| Aftercare | 2 | 2008 | 870 | 0.080 |
Why?
|
| Pro-Opiomelanocortin | 1 | 2009 | 163 | 0.080 |
Why?
|
| Proportional Hazards Models | 5 | 2022 | 12356 | 0.080 |
Why?
|
| Length of Stay | 4 | 2008 | 6311 | 0.080 |
Why?
|
| Mental Health | 3 | 2024 | 3010 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 8 | 2011 | 17446 | 0.080 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 1 | 2009 | 322 | 0.080 |
Why?
|
| Receptor, Cannabinoid, CB1 | 1 | 2008 | 143 | 0.080 |
Why?
|
| Triage | 1 | 2014 | 977 | 0.080 |
Why?
|
| Placebo Effect | 2 | 2008 | 502 | 0.080 |
Why?
|
| Medical Assistance | 1 | 2008 | 104 | 0.070 |
Why?
|
| Self-Assessment | 2 | 2000 | 390 | 0.070 |
Why?
|
| Social Work | 1 | 2009 | 162 | 0.070 |
Why?
|
| Carbamazepine | 2 | 2018 | 229 | 0.070 |
Why?
|
| Chromosome Mapping | 4 | 2010 | 4740 | 0.070 |
Why?
|
| Adolescent Development | 1 | 2010 | 279 | 0.070 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 1989 | 434 | 0.070 |
Why?
|
| Receptors, GABA-A | 1 | 2011 | 627 | 0.070 |
Why?
|
| Veterans | 1 | 2020 | 2519 | 0.070 |
Why?
|
| Patient Care Team | 3 | 1995 | 2531 | 0.070 |
Why?
|
| Dopa Decarboxylase | 1 | 2006 | 15 | 0.070 |
Why?
|
| Cooperative Behavior | 1 | 2014 | 1504 | 0.070 |
Why?
|
| Sensitivity and Specificity | 4 | 2023 | 14723 | 0.070 |
Why?
|
| Child Abuse, Sexual | 3 | 1998 | 383 | 0.070 |
Why?
|
| Neural Cell Adhesion Molecules | 1 | 2006 | 126 | 0.070 |
Why?
|
| Nuclear Family | 4 | 2008 | 318 | 0.070 |
Why?
|
| Social Behavior | 1 | 2013 | 1127 | 0.070 |
Why?
|
| Michigan | 1 | 2007 | 350 | 0.070 |
Why?
|
| Genetic Variation | 4 | 2011 | 6542 | 0.070 |
Why?
|
| Impulsive Behavior | 1 | 2008 | 316 | 0.070 |
Why?
|
| Genotype | 9 | 2011 | 12952 | 0.070 |
Why?
|
| Patient Care Planning | 2 | 2008 | 921 | 0.070 |
Why?
|
| Problem Solving | 1 | 2008 | 440 | 0.070 |
Why?
|
| False Negative Reactions | 1 | 2007 | 588 | 0.070 |
Why?
|
| Pemoline | 1 | 1985 | 18 | 0.070 |
Why?
|
| Cluster Analysis | 5 | 2008 | 2715 | 0.070 |
Why?
|
| Legislation, Drug | 1 | 2007 | 206 | 0.070 |
Why?
|
| Antisocial Personality Disorder | 5 | 1997 | 228 | 0.070 |
Why?
|
| Double-Blind Method | 5 | 2016 | 12025 | 0.070 |
Why?
|
| Siblings | 2 | 2009 | 854 | 0.070 |
Why?
|
| Child | 11 | 2024 | 77709 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2006 | 403 | 0.060 |
Why?
|
| Terminology as Topic | 2 | 2013 | 1547 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2006 | 437 | 0.060 |
Why?
|
| Health Status Indicators | 1 | 2010 | 970 | 0.060 |
Why?
|
| Receptors, Dopamine D2 | 1 | 2006 | 475 | 0.060 |
Why?
|
| Interviews as Topic | 1 | 2011 | 2539 | 0.060 |
Why?
|
| Drug Discovery | 1 | 2012 | 1058 | 0.060 |
Why?
|
| Pregnancy | 3 | 2015 | 29144 | 0.060 |
Why?
|
| Medical Records | 2 | 2012 | 1413 | 0.060 |
Why?
|
| Demography | 2 | 2006 | 1655 | 0.060 |
Why?
|
| Genome, Human | 2 | 2008 | 4420 | 0.060 |
Why?
|
| Probability | 2 | 2023 | 2506 | 0.060 |
Why?
|
| Linkage Disequilibrium | 4 | 2011 | 1997 | 0.060 |
Why?
|
| Immunoassay | 1 | 2007 | 752 | 0.060 |
Why?
|
| Disability Evaluation | 1 | 2010 | 1828 | 0.050 |
Why?
|
| Evidence-Based Medicine | 2 | 2005 | 3611 | 0.050 |
Why?
|
| Negotiating | 1 | 2003 | 133 | 0.050 |
Why?
|
| Administration, Cutaneous | 2 | 2013 | 711 | 0.050 |
Why?
|
| Sick Role | 1 | 2003 | 237 | 0.050 |
Why?
|
| Consensus | 2 | 2022 | 2960 | 0.050 |
Why?
|
| Cohort Studies | 5 | 2023 | 40559 | 0.050 |
Why?
|
| Oregon | 1 | 2022 | 140 | 0.050 |
Why?
|
| Malignant Hyperthermia | 1 | 2001 | 73 | 0.050 |
Why?
|
| Quantitative Trait Loci | 2 | 2008 | 2019 | 0.050 |
Why?
|
| ROC Curve | 1 | 2009 | 3528 | 0.050 |
Why?
|
| Pandemics | 1 | 2021 | 8385 | 0.050 |
Why?
|
| Nitrosamines | 1 | 2021 | 87 | 0.050 |
Why?
|
| Survival Analysis | 3 | 2009 | 10252 | 0.050 |
Why?
|
| Drug Interactions | 1 | 2005 | 1460 | 0.050 |
Why?
|
| Anabolic Agents | 1 | 2003 | 247 | 0.050 |
Why?
|
| Age of Onset | 4 | 2009 | 3270 | 0.050 |
Why?
|
| Guidelines as Topic | 1 | 2007 | 1405 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2010 | 6539 | 0.040 |
Why?
|
| Disease Progression | 2 | 2019 | 13286 | 0.040 |
Why?
|
| Prescriptions | 1 | 2022 | 387 | 0.040 |
Why?
|
| Delphi Technique | 1 | 2022 | 779 | 0.040 |
Why?
|
| Sex Reassignment Procedures | 1 | 2019 | 50 | 0.040 |
Why?
|
| Crack Cocaine | 1 | 1998 | 32 | 0.040 |
Why?
|
| Reimbursement, Incentive | 1 | 2003 | 540 | 0.040 |
Why?
|
| Bulimia | 2 | 1992 | 383 | 0.040 |
Why?
|
| Acetaminophen | 1 | 2022 | 545 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 2 | 2015 | 5388 | 0.040 |
Why?
|
| Social Environment | 2 | 2009 | 1022 | 0.040 |
Why?
|
| Hospitals, Private | 1 | 2017 | 63 | 0.040 |
Why?
|
| Urban Population | 2 | 2019 | 2022 | 0.040 |
Why?
|
| Parents | 1 | 2010 | 3405 | 0.040 |
Why?
|
| Risk Assessment | 4 | 2014 | 23336 | 0.040 |
Why?
|
| Population Surveillance | 1 | 2007 | 2616 | 0.040 |
Why?
|
| Fentanyl | 1 | 2019 | 409 | 0.040 |
Why?
|
| Interpersonal Relations | 1 | 2004 | 1425 | 0.040 |
Why?
|
| Patient Readmission | 2 | 2004 | 3116 | 0.040 |
Why?
|
| Disease | 1 | 2002 | 680 | 0.040 |
Why?
|
| Central Nervous System Depressants | 2 | 1988 | 167 | 0.030 |
Why?
|
| Pedigree | 4 | 2008 | 4642 | 0.030 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2020 | 875 | 0.030 |
Why?
|
| Rehabilitation, Vocational | 1 | 1996 | 82 | 0.030 |
Why?
|
| Self Care | 2 | 1999 | 786 | 0.030 |
Why?
|
| Lod Score | 2 | 2006 | 614 | 0.030 |
Why?
|
| Educational Status | 1 | 2003 | 2540 | 0.030 |
Why?
|
| Psychophysics | 1 | 2016 | 309 | 0.030 |
Why?
|
| Aging | 1 | 2014 | 8664 | 0.030 |
Why?
|
| Drug Combinations | 2 | 2010 | 1958 | 0.030 |
Why?
|
| Physician-Patient Relations | 2 | 2006 | 3229 | 0.030 |
Why?
|
| Pain Perception | 1 | 2016 | 191 | 0.030 |
Why?
|
| Organ Size | 1 | 2019 | 2251 | 0.030 |
Why?
|
| Acyltransferases | 1 | 1996 | 294 | 0.030 |
Why?
|
| Physicians | 1 | 2012 | 4567 | 0.030 |
Why?
|
| Age Distribution | 1 | 2000 | 2902 | 0.030 |
Why?
|
| Lung Volume Measurements | 2 | 1987 | 378 | 0.030 |
Why?
|
| Statistics, Nonparametric | 2 | 2012 | 2887 | 0.030 |
Why?
|
| Brain | 3 | 2010 | 26388 | 0.030 |
Why?
|
| Medicaid | 2 | 2003 | 2737 | 0.030 |
Why?
|
| Cotinine | 1 | 2013 | 206 | 0.030 |
Why?
|
| Accidents | 1 | 2013 | 164 | 0.030 |
Why?
|
| Internship and Residency | 1 | 2012 | 5791 | 0.030 |
Why?
|
| Neurologic Examination | 1 | 1995 | 931 | 0.030 |
Why?
|
| Hyperalgesia | 1 | 2016 | 502 | 0.030 |
Why?
|
| Alleles | 3 | 2009 | 6933 | 0.030 |
Why?
|
| Phenotype | 5 | 2007 | 16367 | 0.030 |
Why?
|
| Health Policy | 1 | 2004 | 2661 | 0.020 |
Why?
|
| Case-Control Studies | 4 | 2011 | 21748 | 0.020 |
Why?
|
| Administration, Sublingual | 1 | 2010 | 56 | 0.020 |
Why?
|
| Cost Control | 1 | 2013 | 624 | 0.020 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2013 | 469 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2005 | 4687 | 0.020 |
Why?
|
| Risk Management | 1 | 2013 | 571 | 0.020 |
Why?
|
| Phencyclidine Abuse | 1 | 1988 | 8 | 0.020 |
Why?
|
| Neuroprotective Agents | 1 | 2016 | 941 | 0.020 |
Why?
|
| National Institute on Alcohol Abuse and Alcoholism (U.S.) | 1 | 2008 | 10 | 0.020 |
Why?
|
| Population | 1 | 2009 | 142 | 0.020 |
Why?
|
| Norepinephrine | 1 | 2011 | 909 | 0.020 |
Why?
|
| Penetrance | 1 | 2010 | 381 | 0.020 |
Why?
|
| Cerebral Ventricles | 1 | 1991 | 544 | 0.020 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 1988 | 361 | 0.020 |
Why?
|
| Algorithms | 2 | 2005 | 13882 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 2009 | 326 | 0.020 |
Why?
|
| Leukocytes | 1 | 1996 | 2045 | 0.020 |
Why?
|
| Family | 2 | 2009 | 3147 | 0.020 |
Why?
|
| Amphetamine | 1 | 1988 | 225 | 0.020 |
Why?
|
| Computational Biology | 1 | 2019 | 3519 | 0.020 |
Why?
|
| Family Relations | 1 | 2009 | 321 | 0.020 |
Why?
|
| Child of Impaired Parents | 1 | 1991 | 455 | 0.020 |
Why?
|
| Medication Errors | 1 | 2013 | 798 | 0.020 |
Why?
|
| Utilization Review | 1 | 2008 | 392 | 0.020 |
Why?
|
| Narcissism | 1 | 1986 | 59 | 0.020 |
Why?
|
| Registries | 1 | 2022 | 8091 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 9240 | 0.020 |
Why?
|
| Mixed Function Oxygenases | 1 | 2006 | 272 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2006 | 323 | 0.020 |
Why?
|
| Homozygote | 1 | 2009 | 1787 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2006 | 417 | 0.020 |
Why?
|
| National Institutes of Health (U.S.) | 2 | 1999 | 780 | 0.020 |
Why?
|
| Agoraphobia | 1 | 2004 | 179 | 0.020 |
Why?
|
| Dopamine | 1 | 2011 | 1591 | 0.010 |
Why?
|
| Placebos | 1 | 2008 | 1676 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2014 | 6896 | 0.010 |
Why?
|
| Cost Allocation | 1 | 2003 | 51 | 0.010 |
Why?
|
| Language | 1 | 2013 | 1471 | 0.010 |
Why?
|
| Introns | 1 | 2006 | 992 | 0.010 |
Why?
|
| Multienzyme Complexes | 1 | 2006 | 686 | 0.010 |
Why?
|
| Microsatellite Repeats | 1 | 2005 | 802 | 0.010 |
Why?
|
| Arousal | 1 | 1989 | 1164 | 0.010 |
Why?
|
| Anorexia Nervosa | 1 | 1992 | 1286 | 0.010 |
Why?
|
| Amygdala | 1 | 2010 | 1315 | 0.010 |
Why?
|
| Mental Recall | 1 | 1989 | 1206 | 0.010 |
Why?
|
| Genetic Markers | 1 | 2009 | 2634 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2010 | 3914 | 0.010 |
Why?
|
| Syndrome | 1 | 1988 | 3252 | 0.010 |
Why?
|
| Genetic Testing | 1 | 2014 | 3444 | 0.010 |
Why?
|
| Emergency Medical Services | 1 | 2013 | 1917 | 0.010 |
Why?
|
| Epidemiologic Methods | 1 | 2006 | 1364 | 0.010 |
Why?
|
| Panic Disorder | 1 | 2004 | 616 | 0.010 |
Why?
|
| Psychotherapeutic Processes | 1 | 2001 | 50 | 0.010 |
Why?
|
| Delivery of Health Care | 1 | 2019 | 5321 | 0.010 |
Why?
|
| Family Health | 1 | 2005 | 1281 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2009 | 6171 | 0.010 |
Why?
|
| Schizophrenic Psychology | 1 | 2007 | 1678 | 0.010 |
Why?
|
| Students | 1 | 2009 | 1647 | 0.010 |
Why?
|
| Neural Pathways | 1 | 2010 | 2974 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 2009 | 4328 | 0.010 |
Why?
|
| Academic Medical Centers | 1 | 2009 | 2760 | 0.010 |
Why?
|
| Nerve Net | 1 | 2010 | 2175 | 0.010 |
Why?
|
| Aggression | 1 | 2003 | 753 | 0.010 |
Why?
|
| Oxygen | 2 | 1998 | 4189 | 0.010 |
Why?
|
| DNA | 1 | 2011 | 7294 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2008 | 4805 | 0.010 |
Why?
|
| Bayes Theorem | 1 | 2005 | 2307 | 0.010 |
Why?
|
| Carbon Dioxide | 1 | 1981 | 1150 | 0.010 |
Why?
|
| Random Allocation | 1 | 2001 | 2428 | 0.010 |
Why?
|
| Gene Expression | 1 | 2009 | 7798 | 0.010 |
Why?
|
| Animals | 1 | 2007 | 168768 | 0.010 |
Why?
|
| Lymphocyte Subsets | 1 | 1996 | 315 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2005 | 3493 | 0.010 |
Why?
|
| Basal Ganglia | 1 | 1998 | 546 | 0.010 |
Why?
|
| Combat Disorders | 1 | 1997 | 302 | 0.010 |
Why?
|
| Tomography, Emission-Computed | 1 | 1998 | 1144 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 1998 | 1525 | 0.010 |
Why?
|
| Internal-External Control | 1 | 1996 | 363 | 0.010 |
Why?
|
| Electroencephalography | 1 | 1989 | 6151 | 0.010 |
Why?
|
| Recovery of Function | 1 | 2003 | 2926 | 0.010 |
Why?
|
| Parietal Lobe | 1 | 1998 | 838 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 2 | 1998 | 35425 | 0.010 |
Why?
|
| Incidence | 2 | 2006 | 20952 | 0.010 |
Why?
|
| Health Personnel | 1 | 2005 | 3219 | 0.010 |
Why?
|
| Gyrus Cinguli | 1 | 1998 | 1091 | 0.010 |
Why?
|
| Clinical Protocols | 1 | 1997 | 1461 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2010 | 12262 | 0.010 |
Why?
|
| Health Expenditures | 1 | 2003 | 2349 | 0.010 |
Why?
|
| Poisson Distribution | 1 | 1992 | 513 | 0.010 |
Why?
|
| Marriage | 1 | 1992 | 339 | 0.010 |
Why?
|
| Temporal Lobe | 1 | 1998 | 1670 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 1996 | 3702 | 0.010 |
Why?
|
| Personality Tests | 1 | 1989 | 83 | 0.010 |
Why?
|
| Reference Values | 1 | 1996 | 4982 | 0.010 |
Why?
|
| Health Services Accessibility | 1 | 2006 | 5135 | 0.010 |
Why?
|
| Methoxyhydroxyphenylglycol | 1 | 1988 | 93 | 0.000 |
Why?
|
| Fatty Acids | 1 | 1996 | 1809 | 0.000 |
Why?
|
| Monoamine Oxidase | 1 | 1988 | 178 | 0.000 |
Why?
|
| Prefrontal Cortex | 1 | 1998 | 2147 | 0.000 |
Why?
|
| Evoked Potentials, Auditory | 1 | 1989 | 525 | 0.000 |
Why?
|
| Child, Preschool | 1 | 2008 | 41005 | 0.000 |
Why?
|
| Job Satisfaction | 1 | 1989 | 534 | 0.000 |
Why?
|
| Aged, 80 and over | 1 | 2009 | 57776 | 0.000 |
Why?
|
| Reaction Time | 1 | 1989 | 2098 | 0.000 |
Why?
|
| Blood Platelets | 1 | 1988 | 2509 | 0.000 |
Why?
|